Swiss Pharma Exports to Russia Remain Stable Despite Conflict

Despite the ongoing conflict in Ukraine, Swiss pharmaceutical exports to Russia have remained remarkably stable, maintaining pre-war levels at CHF1.8 billion in 2024. This stability persists more than three and a half years after Moscow's invasion of Ukraine, highlighting Switzerland's unique position in maintaining medical trade relationships. According to the Federal Customs and Border Security Service (FCAB), these figures slightly decreased from the previous two years but match 2019 pre-pandemic levels. Notably, pharmaceutical products now constitute over 80% of Swiss exports to Russia, a significant increase from the 50% share before the conflict began in February 2022.

The continuation of pharmaceutical exports has sparked a debate between humanitarian necessity and political responsibility. While these exports are legally permitted under current sanctions, which exclude humanitarian and medical products, voices like Public Eye, a Swiss NGO, advocate for withdrawal from the Russian market. The organization argues that alternatives exist for essential medications and suggests limiting supply to clinical trials only. However, pharmaceutical companies maintain that ensuring continuous access to medicines for patients transcends political boundaries, emphasizing their global humanitarian responsibilities.

Leading Swiss pharmaceutical companies have taken varied approaches while maintaining their presence in Russia. Novartis emphasizes its commitment to global medical access, regardless of geographical location. Roche has significantly restricted its activities while ensuring essential drug supply, with Russia representing approximately 1% of its global turnover. Sandoz reports that about half of its Russian market products are on the WHO's essential medicines list. Lonza maintains very limited business relations with Russia, having no physical presence in the country. These positions reflect a careful balance between corporate responsibility and humanitarian obligations.

The continued pharmaceutical trade with Russia raises significant economic and ethical questions. While Russia represents less than 2% of total Swiss pharmaceutical exports, the symbolic importance of these transactions extends beyond their monetary value. Public Eye argues that while these exports may not significantly finance Russian military activities, a withdrawal would send a powerful political message. The situation highlights Switzerland's traditional role as a neutral state and its commitment to humanitarian principles, even in times of international conflict. This balance between maintaining essential medical supplies and responding to international political pressure continues to shape Switzerland's approach to this sensitive trade relationship.